Urinary incontinence

CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, NIHCC, FLA, NIH, Male, Urinary incontinence, Erectile dysfunction, CLS, Bangladesh Technical Education Board, Medical imaging

LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.

Key Points: 
  • LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.
  • The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.
  • “This second order of our TRANBERG Focal Laser Ablation accessories enables our continued collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas.
  • It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, tissue temperature probes, and procedure-specific accessories.

CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation

Retrieved on: 
Thursday, March 28, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, Cancer, Prostate, FLA, Urinary incontinence, Erectile dysfunction, CLS, FDA, Physician, Medical imaging

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.

Key Points: 
  • LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.
  • The system is FDA 510(k) cleared for soft tissue ablation in a urology setting.
  • Operating under CLS's Mobile Services Agreement, CLS will provide its FDA 510(k) cleared TRANBERG Laser, consumable accessories, training, and on-site clinical and technical support to ROSE Urology physicians and staff during procedures.
  • Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.

SpineX Closes Recruitment for SCONE™ Clinical Trial

Retrieved on: 
Monday, April 8, 2024
Children, Biotechnology, FDA, Health, Neurology, Health Technology, Medical Devices, Research, Consumer, Science, Clinical Trials, Cord, Brain, Cerebral palsy, Multiple sclerosis, SCIP, Patient, Stroke, Clinical trial, Urinary bladder, Trial of the century, Skin, Spinal cord, Heart, Urinary incontinence, Cauda equina syndrome, Neuromodulation, Pharmaceutical industry

SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.

Key Points: 
  • SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.
  • The clinical trial— Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study — began in May 2022.
  • “SCONE has the power to transform the lives of millions of patients with neurogenic bladder,” says Parag Gad, SpineX co-founder & CEO.
  • SpineX anticipates beginning a multi-center pivotal trial for children with Cerebral Palsy in 2024.

BlueWind Medical Revi™ Patient-Centric Solution for Urge Urinary Incontinence Now Available at Mount Carmel Health in Ohio

Retrieved on: 
Tuesday, April 9, 2024
Physician, Patient, Tibial, OASIS, Ankle, Quality of life, Pharmacotherapy, Urinary incontinence, Safety, Commercial software, Neuromodulation, FDA, Medical device

PARK CITY, Utah, April 9, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a trailblazer in patient-centric healthcare innovations, announced that distinguished urologist Dr. Jeffrey Carey of the Central Ohio Urology Group is now offering Revi implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI).

Key Points: 
  • PARK CITY, Utah, April 9, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a trailblazer in patient-centric healthcare innovations, announced that distinguished urologist Dr. Jeffrey Carey of the Central Ohio Urology Group is now offering Revi implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI).
  • "Many of my patients are looking for an alternative to ongoing drug therapy" shared Dr. Jeffrey Carey.
  • "Revi provides individually tailored therapy that patients deliver themselves, on their schedule, and at their convenience.
  • Coupled with the excellent safety and efficacy of Revi, it's a welcome choice for urge incontinence patients."

Juniper Biomedical Secures Seed Funding to Accelerate Growth and Innovation in Pelvic Health Disorders.

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Professional Services, Health, General Health, Women, Venture Capital, Health Technology, Other Science, Medical Devices, Consumer, Science, Biomedicine, Growth, Urinary incontinence, Entrepreneurship, MUI, Patient, Pelvic pain, Incontinence, NIH, Woman, Ecosystem, Medtech, Pharmaceutical industry

The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.

Key Points: 
  • The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.
  • "We believe that Juniper Biomedical has tremendous potential for growth and disruption in pelvic health in the historically underserved patient populations," said Larry Derose, founder of Auroral Holdings.
  • Juniper Biomedical is developing dramatically better therapies for the millions of women and men who suffer in silence from pelvic health conditions like urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders.
  • Our solutions leverage a highly precise, low-power neuromodulation micro-implant that delivers a unique type of therapy to pelvic nerves.

EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market

Retrieved on: 
Friday, March 29, 2024
Consumer Electronics, Health, Consumer, Technology, Women, Fitness & Nutrition, Hardware, KRW, Yong In University, Uterus, Exercise, Lifting, Relaxation, Beauty, Pelvis, Rectum, Pregnancy, PMS, Menstruation, Femininity, Nocturia, Uterine prolapse, Pelvic floor, Traction, Urinary incontinence, Elasticity, Premenstrual syndrome, EMS, Multimedia, Dietary supplement

This innovative solution enables people to do Kegel exercises easily by sitting on it, heralding a new era of K-HEALTH CARE.

Key Points: 
  • This innovative solution enables people to do Kegel exercises easily by sitting on it, heralding a new era of K-HEALTH CARE.
  • View the full release here: https://www.businesswire.com/news/home/20240327264174/en/
    The EMS Kegel Trainer BODYDOCTOR FEMFIT has been launched in Japan.
  • (Photo: GENERALNET CORP)
    Derived from combining 'Feminine' and 'Care', the term 'Femcare' encompasses products and services designed to care for women’s bodies and health.
  • Understanding how important it is to strengthen pelvic floor muscles to address these health issues, GENERALNET CORP, a company dedicated to women's health and beauty, launched the EMS Kegel exerciser BODYDOCTOR in January 2019.

Pelvital Announces Advisory Board, Fueling its Mission to Transform the Standard of Care for Urinary Incontinence

Retrieved on: 
Tuesday, April 2, 2024
University, Obstructive sleep apnea, Patient, Pelvic pain, Vocational education, Urodynamic testing, Engineering, Gender, Champaign–Urbana metropolitan area, Pelvic organ prolapse, Carlson School of Management, UnitedHealth Group, Incontinence, Woman, Safety, Strategic communication, Organization, Biomedical engineering, Advisory board, Neurology, Female, Sport, Associate, Research, MD, UIT, Tetraplegia, Urinary incontinence, Biology, Book, FDA, Medtech, Health, Visibility, Growth, Computational biology, Arizent, Mechanical engineering, Physiology, M Health Fairview, Doctor of Philosophy, Integrative Biology, Faculty, Urogynecology, Human, MBA, News, Government, Rehabilitation, Nursing

EAGAN, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- Pelvital, the women's health MedTech company on a mission to transform the standard of care for urinary incontinence, is proud to announce the formation of its formal scientific and business advisory board. This dynamic team of industry leaders and experts will play a pivotal role in supporting the strategic direction and growth of the organization in its ongoing efforts to expand its reach with clinicians, patients, and payors seeking an effective, accessible, conservative treatment option.

Key Points: 
  • EAGAN, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- Pelvital, the women's health MedTech company on a mission to transform the standard of care for urinary incontinence, is proud to announce the formation of its formal scientific and business advisory board.
  • The seven-person advisory board assembles a wealth of experience and expertise with each member having a proven track record of excellence.
  • Dr. Alpert has taught for many years in entrepreneur programs at U.S. and overseas universities, mentoring students and faculty working in the healthcare industry.
  • Their collective knowledge and experience will be instrumental in guiding Pelvital as we embark on an exciting phase of growth and innovation."

Patients in Utah Now Have Access to the Novel Revi™ Implantable Tibial Neuromodulation Device for the Treatment of Urge Urinary Incontinence

Retrieved on: 
Wednesday, March 27, 2024
Physician, Patient, OASIS, University, Ankle, Quality of life, Pharmacotherapy, Urinary incontinence, Commercial software, Neuromodulation, FDA

PARK CITY, Utah, March 27, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient-centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Revi is now available in Utah with urologist Dr. Sara Lenherr at the University of Utah.

Key Points: 
  • "Revi is a solution for the millions of people dealing with Urge Urinary Incontinence (UUI).
  • I look forward to offering Revi to my patients, especially those who are unable to tolerate, afford, or are not good candidates for drug therapy," shared Dr. Sara Lenherr.
  • "Revi offers a patient-centered design, which allows for individually tailored therapy that patients can deliver themselves, on their schedule and at their convenience."
  • UUI is a common and debilitating condition, affecting approximately 16 million people in the U.S., most of whom never receive effective treatment.

New treatment option for prostate cancer shows successful outcomes

Retrieved on: 
Saturday, March 23, 2024
Disease, Radiation, Cryotherapy, Hatred, Collateral damage, MRI, Prostate cancer, Average revenue per user, Urology, Heat, FASR, Risk, Patient, Lung, Neoplasm, Research, Cancer, Calcification, Standard of care, Radiology, Prostate, Society, Urinary incontinence, Kidney, Erectile dysfunction, PCA, PSA, UCLA, Urethra, Medical imaging

FAIRFAX, Va., March 23, 2024 /PRNewswire/ -- A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City.

Key Points: 
  • "Prostate cancer is the most common form of cancer in men, affecting one in eight men in their lifetimes.
  • According to Dr. Raman, "This image-guided therapy maximizes our ability to kill cancer cells while minimizing collateral damage to the prostate to achieve the ultimate trifecta in prostate cancer treatment: full local cancer control while maintaining urinary continence and potency.
  • The latter are the complications of most prostate cancer therapies that patients hate and often result from a lack of precision in treatment monitoring."
  • Abstract #135 : Five-year outcomes after MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer.

BlueWind Medical Revi™ Implantable Tibial Neuromodulation Device Now Available to Patients in Texas

Retrieved on: 
Thursday, March 21, 2024
De novo, American Medical Association, Urinary bladder, Renaissance, Patient, Ankle, Quality of life, Surgeon, CPT, Urinary incontinence, Commercial software, Urology, Medicare, Neuromodulation, USD, FDA, CMS, Health, Food

PARK CITY, Utah, March 21, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Urologists Dr. Henry Ruiz and Dr. Natalia Hernandez at the Urology Institute at Renaissance are the first providers of Revi in the state of Texas.

Key Points: 
  • "Urge Incontinence, although a common condition with profound impacts on quality of life, has long been under-diagnosed and under-treated.
  • With the advent of Revi, we now have a safe and proven patient-centric solution that can be tailored and optimized to meet the needs of patients," stated Dr. Ruiz.
  • In October 2023, the American Medical Association (AMA) CPT Editorial Panel announced the final Current Procedural Terminology (CPT) code to describe the subfascial tibial neuromodulation implant procedure, 0817T.
  • We consider it a privilege to contribute to improving the quality of life for the millions living with urge incontinence," stated Dan Lemaitre, Chief Executive Officer of BlueWind Medical.